ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

WEARABLES

DIVERGENT DESIGN PHILOSOPHIES IN THE WEARABLE INJECTOR SEGMENT

Reto Jost and Daniel Käser detail how Ypsomed is approaching wearable injector design with YpsoDose and achieving large-volume requirements, consistent dosing and low residual waste, going on to explain how the company’s design choices are integrated with patient-centric features to ensure adherence and comfort.

ON-BODY INJECTORS: A PROMISING SOLUTION TO THE UK’S SYSTEMIC ANTI-CANCER THERAPY CRISIS

Omar Rahman, Catherine Loughran and Rachel Senior consider how on-body injectors, such as Enable’s enFuse, can help to reduce the administrative burden on the healthcare system as well as giving patients more autonomy and dignity in managing their disease.

REDEFINING PATIENT-CENTRIC DRUG DELIVERY: A CLOSER LOOK AT VERTIVA^® ON-BODY DELIVERY SYSTEM

Anna Allegro explores current challenges in wearable injectors and how the next generation of on-body delivery systems, such as Stevanato’s Vertiva^® platform, aims to close the gap between technical performance and true patient centricity.

SYMBIOZE<sup>®</sup> – THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES

SYMBIOZE^® – THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES

Corinne Malica and Cécile Gross discuss the challenges involved in developing a wearable device for on-body drug delivery of advanced biologics, with a focus on the immunotherapy sector, and the technical solutions that can overcome them, using Nemera’s Symbioze^® as an example.

ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE

ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE

Dr Greg Moakes discusses the role that on-body delivery systems have to play in modernising the delivery of oncology drugs, digging into the survey results of over 200 attendees of the American Society of Clinical Oncology 2025 Global Meeting as to their opinions on the place of this pivotal technology in oncological practice.

DEVICE DESIGN TO ADDRESS USABILITY AND MITIGATE USE-RELATED RISKS – A MEDICAL AFFAIRS AND HUMAN FACTORS PERSPECTIVE

Dr Sylvine Raverdy-Wilson

BD (Becton Dickinson & Company)

DEVICE DESIGN TO ADDRESS USABILITY AND MITIGATE USE-RELATED RISKS – A MEDICAL AFFAIRS AND HUMAN FACTORS PERSPECTIVE

Dr Sylvine Raverdy-Wilson deep dives into the device constituent of drug-device combination product design and shares perspectives through the Use-Related Risk Analysis methodology with a focus on the BD Libertas™ Wearable Injector.

VISTA BY TXSPHERE: TRAVERSING THE LIMITATIONS OF SMALL-VOLUME BIOLOGICS

Dr Chaoyoung Lee

VISTA BY TXSPHERE: TRAVERSING THE LIMITATIONS OF SMALL-VOLUME BIOLOGICS

Dr Chaoyoung Lee and Mike Stout unveil an innovative addition to TxSphere's wearable platform, Vista, designed to improve on efficiency goals, adapt to varied drug formulations and advance beyond the requirements of low-volume drug delivery.

INJECTING DRUGS DIRECTLY INTO THE BODY: HOW ON-BODY DELIVERY SYSTEMS ARE REVOLUTIONISING THERAPY

INJECTING DRUGS DIRECTLY INTO THE BODY: HOW ON-BODY DELIVERY SYSTEMS ARE REVOLUTIONISING THERAPY

Peter Schmidt discusses the advantages of on-body delivery systems and what makes them special, going on to consider the significant role that they are expected to play in the future of injection technology for the pharmaceutical and medical fields, as well as the role that comprehensive testing plays in bringing this technology to patients.

ACCELERATING DEVELOPMENT OF ELECTROMECHANICAL DELIVERY SYSTEMS VIA MODULAR INTEGRATION

Nicholas Ciccarelli

ACCELERATING DEVELOPMENT OF ELECTROMECHANICAL DELIVERY SYSTEMS VIA MODULAR INTEGRATION

Nicholas Ciccarelli, Andrew King, Dr Marcus Herrmann and Dr Thomas Roschke, discuss the insights gained in the product development process from the recent collaboration between the two companies, with Kymanox managing the overall system integration and Johnson MedTech tackling the specific design of the drive system within the designated product specification.

SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING

Michael Boerner

SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING

Michael Boerner looks at the key factors for designing skin-friendly medical wearables and how to manufacture them safely, automatically and sustainably.

SELF-INJECTION DEVICE MANUFACTURING IN A DYNAMIC WORLD

INDUSTRIALISATION

Philipp Richard

SELF-INJECTION DEVICE MANUFACTURING IN A DYNAMIC WORLD

Philipp Richard scrutinises the efficient production of self-injection devices in the pharma industry and describes Ypsomed’s own platforms for developing these devices, highlighting the need to be adaptable and resilient to the rapidly evolving world of drug development. He provides valuable insights into the ways in which the flexible manufacture of self-injection devices might be achieved.

Interview: SHL Advantec – SHL Medical’s New Manufacturing Equipment Sub-Group

Gilbert Fluetsch

Interview: SHL Advantec – SHL Medical’s New Manufacturing Equipment Sub-Group

Gilbert Fluetsch discusses the establishment of SHL Advantec and the foundation it has built as SHL Medical’s in-house equipment specialist. Mr Fluetsch also looks at the role of modular platforms in scaling production and how the company’s global network is designed to support the changing landscape of medical and pharma manufacturing.

FINDING COMMON GROUND: FACTORS FOR ESTABLISHING AND SAFEGUARDING SHELF LIFE IN COMBINATION PRODUCTS

INDUSTRIALISATION

West Pharmaceutical Services

FINDING COMMON GROUND: FACTORS FOR ESTABLISHING AND SAFEGUARDING SHELF LIFE IN COMBINATION PRODUCTS

Lauren Orme discusses the regulatory considerations that need to be taken into account when designing combination products. She reviews the essential testing and standards required for both drug and device when establishing their shelf life and storage in a combined product.

Interview From Pilot to Scale Manufacturing

Interview From Pilot to Scale Manufacturing

In this second exclusive interview with ONdrugDelivery, Glenn Svedberg talks with Guy Furness about Nolato’s role as a strategic partner for design, development and industrialisation within the pharmaceutical sector. In an engaging conversation, Mr Svedberg covers a wide range of subjects about Notalo, including the company’s virtual factory, decentralised structure, approach to scaling up from single-cavity moulds to commercial production, regulatory expertise and global footprint, discussing how the company can use each of these elements to support its partners’ device development and industrialisation programmes.

SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN

INDUSTRIALISATION

SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN

Louise Righton examines the potential for reducing emissions across the pMDI supply chain, considering the localisation of suppliers to shorten supply chains as well as strong partnerships for developing novel, low-carbon alternatives to current high-emission pMDI manufacturing processes.

CDMOs AS STRATEGIC ENABLERS FOR DEVICE INDUSTRIALISATION

INDUSTRIALISATION

Adam Nightingale

CDMOs AS STRATEGIC ENABLERS FOR DEVICE INDUSTRIALISATION

Adam Nightingale explores a multitude of approaches to achieving more efficient and sustainable production of medical devices when partnering with a CDMO, and demonstrates the ways in which these partnerships can offer reduced risk and comply with regulations when streamlining industrialisation.

Interview: Phillips Medisize Grows its Capabilities with Vectura

Phillips Medisize

Interview: Phillips Medisize Grows its Capabilities with Vectura

In this exclusive interview with ONdrugDelivery’s Guy Furness, Brian Thompson and Dave Thoreson discuss Phillips Medisize’s expanded capabilities as a result of its recent acquisition of Vectura, bringing extensive expertise and experience in the inhalation sector within the global CDMO. The discussion covers how Phillips Medisize organises its global operations, the opportunities that the acquisition of Vectura represents and where the company goes next.

MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES

Jennifer Gattari

MASTERING COMMERCIAL MANUFACTURING FOR STERILE INJECTABLES

Jennifer Gattari delves into what is required to succeed at the commercial phase of sterile injectable manufacturing, going on to explore the challenges that companies can expect and the critical strategies that can help ensure a smooth and scalable journey to market.

PRESSURE ON THE SUPPLY CHAIN: TARIFFS, REGULATIONS AND TRANSPARENCY

PRESSURE ON THE SUPPLY CHAIN: TARIFFS, REGULATIONS AND TRANSPARENCY

Jacob Tyson and Jon Lawrence consider the changes in the regulatory landscape for medical device manufacturers; the critical role that suppliers, distributors and importers play in ensuring effective post-market surveillance; and the technologies that companies are adopting to support traceability solutions.

HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL

Dr Richard Parmee

HARNESSING X-RAY AND AI FOR A NEW ERA OF QUALITY CONTROL

Dr Richard Parmee discusses the multitudinous applications of X-ray inspection technology for high-speed pharmaceutical production lines, covering the value of introducing artificial intelligence and machine learning techniques to enhance detection and improve safety.

INTEGRATING DIGITAL HEALTH SYSTEMS INTO MEDICAL DEVICE ECOSYSTEMS: CONSIDERATIONS & STRATEGIES

EdgeOne Medical

INTEGRATING DIGITAL HEALTH SYSTEMS INTO MEDICAL DEVICE ECOSYSTEMS: CONSIDERATIONS & STRATEGIES

Jerzy Wojcik and Liat Shochat take a look at how digital health technologies are transforming the pharmaceutical and combination product sectors. They consider the challenges in bringing these technologies to market and how the full potential of connected health technologies can be achieved.

NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs

NAVIGATING SEMICONDUCTOR LIFECYCLE CHALLENGES IN MEDTECH: A STRATEGIC SHIFT TOWARDS ASICs

Andy Kelly considers the evolution of semiconductor technology and the impact of the release of new and upgraded components. This article discusses how strategic decisions during the early stages of product design can determine the future viability of a medical device and considers the cost savings offered by application-specific integrated circuits through a reduction in the number of components required.

CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES

Dr Joachim Wilke

CONNECTED BUT PROTECTED – SECURELY CONNECTING DRUG DELIVERY DEVICES

Dr Joachim Wilke discusses wireless connectivity in novel drug delivery devices, highlighting the possibilities for improved patient outcomes and care, the associated security risks, as well as examining the wide range of cyber security solutions and standards to mitigate these issues.

SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST

SMART ENOUGH: DESIGNING DRUG DELIVERY DEVICES THAT PUT PATIENTS FIRST

Andy Pidgeon challenges the assumption that more advanced technology is always better, re-examining the design approach to connected autoinjectors from the patient perspective and highlighting the value of simplicity and usability – digging into the idea that, by investigating the real-world needs of patients, drug delivery device designers can ensure that their devices are serving those needs, rather than creating unnecessary new challenges for users.

Interview: PDA Miniverse and Trends in Injectable Drug Delivery

Mathias Romacker

Interview: PDA Miniverse and Trends in Injectable Drug Delivery

In this exclusive interview, Mathias Romacker and Evan Edwards talk with ONdrugDelivery’s Guy Furness about the upcoming inaugural PDA Miniverse conference in Indianapolis, and the topics and trends currently being felt across the injectable drug delivery industry.

Interview: Patient Experience Versus Regulatory Compliance – Can Formulators Find a Middle Ground?

Dr Keat Theng Chow

Interview: Patient Experience Versus Regulatory Compliance – Can Formulators Find a Middle Ground?

Dr Keat Theng Chow outlines the essential themes on Roquette’s radar regarding patient-centric drug design, upcoming regulatory changes and how drug producers can navigate both spheres to the benefit of all.

TPDs: DEVELOPING THE NEXT GENERATION OF ORAL THERAPEUTICS

Dr Anshul Gupte

PCI Pharma Services

TPDs: DEVELOPING THE NEXT GENERATION OF ORAL THERAPEUTICS

Dr Anshul Gupte looks at how targeted protein degraders are redefining the landscape of drug delivery, creating new strategies for previously untreatable diseases. The article goes on to consider the scientific, manufacturing and regulatory challenges ahead, while considering the role specialised CDMOs can play in overcoming these obstacles.

1
2
3
…
65
Next

See what ondrugdelivery's readers and contributors think

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Top